BioTime Presents Retinal Restoration Data at ARVO
May 11 2017 - 7:00AM
Business Wire
Demonstrates Ability to Grow Full-Thickness,
3-D Retinal Tissue
Tissue is Highly Similar to Natural Human
Tissue
BioTime, Inc. (NYSE MKT: BTX), a clinical-stage
biotechnology company developing and commercializing products
addressing degenerative diseases, today announced that a poster
related to the Company’s retinal restoration technology was
presented at the Annual Meeting of the Association for Research in
Vision and Ophthalmology (ARVO) in Baltimore, Maryland on May 11,
2017.
BioTime scientists have grown full-thickness, 3-D retinal tissue
using the Company’s proprietary pluripotent cellular platform. This
tissue contains all the cell types that comprise the human retina,
including RPE cells, photoreceptors and ganglion cells. Data
presented at ARVO demonstrates that BioTime’s 3-D retinal tissue
closely resembles young, natural human retinal tissue. The
technology may ultimately be used to repair and restore sections of
degenerated retinal tissue and possibly help restore visual
function, irrespective of the condition that caused vision loss or
blindness. Study authors conclude the Company’s 3-D retinal tissue
may address the limiting factor of implementing a retinal
restoration strategy to address severe retinal degenerative
diseases, the availability of mutation-free retinal tissue.
“We are building a pipeline of ophthalmic therapeutics that can
be efficiently manufactured in a lab,” stated Adi Mohanty, Co-Chief
Executive Officer. “We are combining our regenerative medicine
expertise and our pluripotent cell technology platform with current
ophthalmic transplant techniques to develop therapeutics that
address many degenerative diseases of the eye.”
More information about the 3-D retinal tissue study is available
here.
About BioTime
BioTime, Inc. is a clinical-stage biotechnology company focused
on developing and commercializing novel therapies developed from
what the company believes to be the world’s premier collection of
pluripotent cell assets. The foundation of BioTime’s core
therapeutic technology platform is pluripotent cells that are
capable of becoming any of the cell types in the human body.
Pluripotent cells have potential application in many areas of
medicine with large unmet patient needs, including various
age-related degenerative diseases and degenerative conditions for
which there presently are no cures. Unlike pharmaceuticals that
require a molecular target, therapeutic strategies based on the use
of pluripotent cells are generally aimed at regenerating or
replacing affected cells and tissues, and therefore may have
broader applicability than pharmaceutical products. BioTime also
has significant equity holdings in two publicly traded companies,
Asterias Biotherapeutics, Inc. and OncoCyte Corporation, which
BioTime founded and which, until recently, were majority-owned
consolidated subsidiaries of BioTime.
BioTime common stock is traded on the NYSE MKT and TASE
under the symbol BTX. For more information, please
visit www.biotimeinc.com or connect with the company
on Twitter, LinkedIn, Facebook, YouTube,
and Google+.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170511005464/en/
Investor Contact:EVC Group, Inc.Brian Moore,
310-770-0389bmoore@evcgroup.comorMedia
Contact:JQA Partners, Inc.Jules Abraham,
917-885-7378jabraham@jqapartners.com
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Sep 2023 to Sep 2024